A Study on the Long-term Non-small Cell Lung Cancer Survivors in the Expand Access Program of Gefitinib in China
Chinese Journal of Lung Cancer, 06/15/2012
Li L et al. – A 250 mg dose of gefitinib offers good QoL and is safe for advanced Non–small Cell Lung Cancer long–term survivors even after more than three years of treatment. According to the evaluation of the current tumor control statuses of patients, gefitinib demonstrates good efficacy in these active long–term survivors.